Patent intelligence · US
US 12201673
Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
Patent details — US 12201673
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 21, 2025
- Expiration
- Jan 16, 2045
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Claims
- 21
- CPC classes
- A61K, A61K38/1709, A61K38/1793, A61K38/2006
Quick answer
US 12201673 (Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Jan 21, 2025. Expires Jan 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K38/1709, A61K38/1793, A61K38/2006, A61K39/395, A61K47/68
More from REGENERON PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421512
CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
granted -
US 12421317
Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies
granted -
US 12421315
CLL-1 targeted immunotherapies
granted -
US 12419963
Diels-Alder conjugation methods
granted -
US 12415856
EGFR x CD28 multispecific antibodies
granted -
US 12410442
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
granted -
US 12404505
Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
granted -
US 12402611
Genetically modified mice and engraftment
granted
Frequently asked questions
What is US patent 12201673?
US 12201673 (Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Jan 21, 2025. Expires Jan 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12201673?
REGENERON PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 837 pharmaceutical patents for this assignee.
When does US 12201673 expire?
Our index shows an expiration date of Jan 16, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.